Latest Amines Stories

Preclinical Study Provides Potential Mechanisms for Lower Cardiotoxicity in Patients with Multiply Relapsed or Refractory Aggressive B-cell NHL Treated with PixuvriTM Who Received Prior Doxorubicin Therapy

2012-12-17 04:21:51

SEATTLE, Dec. 17, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced the publication of results from a preclinical study of Pixuvri(TM) (pixantrone) in the The Journal of Pharmacology and Experimental Therapeutics providing potential mechanisms for lower cardiotoxicity in patients treated with Pixuvri who received prior doxorubicin therapy. While CHOP-R is considered an effective therapy and is the standard of care in first line treatment of...

Current Situation Of Lung Cancer Treatment

2012-12-11 16:10:39

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care. “We’re in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure,” Bunn says. The review describes the shift from blanketing lung...

Rapid-Acting Antidepressants Reviewed by NeuroPerspective

2012-12-11 08:24:39

CARDIFF, Calif., Dec. 11, 2012 /PRNewswire/ -- NI Research has released the December issue of NeuroPerspective, which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the programs developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine. This 29-page issue includes:1) An overview of the biology of depression and the implications of accelerated...

Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours

2012-12-06 08:26:22

HOLLYWOOD, Fla. and EVANSTON, Ill., Dec. 6, 2012 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13. GLYX-13 is a novel partial agonist of the NMDA receptor. The Phase Ila results are being presented this week at the 51(st) Annual Meeting of the American College of...

Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Company's Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression

2012-12-05 08:26:31

SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- BrainCells, Inc. (BCI), a leading biotechnology company developing novel compounds for the treatment of central nervous system (CNS) diseases, announced the successful completion of their Phase 1 multiple ascending dose (MAD) study of BCI-838, the oral prodrug for the company's Group II mGluR2/3 antagonist, BCI-632. BCI will advance the clinical development program of the compound by initiating a Proof-of-Concept (PoC) study in patients with...

Study indicates a quarter of lung cancer patients did not receive Pharmacogenomic testing prior to start of treatment

2012-11-30 08:24:30

ST. PAUL, Minn., Nov. 30, 2012 /PRNewswire/ -- Nearly a quarter of patients taking erlotinib (Tarceva®) for treatment of advanced non-small cell lung cancer (NSCLC) did not receive the recommended pharmacogenomic (PGx) testing prior to the start of treatment, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime), in collaboration with Jonas de Souza, MD, Instructor of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center. The study...

Chimerix To Present At Therapeutic Area Partnerships Meeting

2012-11-26 08:23:53

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that President and Chief Executive Officer Kenneth I. Moch will present at the 2012 Therapeutic Area Partnerships meeting in Boston, MA. His presentation will include an update on the company's clinical pipeline, including its lead development compound, CMX001, which was named by conference organizers a "Top 10...

Physician-Patient Alliance for Health & Safety: Addressing The Joint Commission Opioid Warnings Can Reduce Respiratory Depression and Improve Patient Safety in Hospitals

2012-11-20 12:27:07

CHICAGO, Nov. 20, 2012 /PRNewswire/ -- The Physician-Patient Alliance for Health & Safety says recent research demonstrates how hospitals can address The Joint Commission Sentinel Event Alert, "Safe Use of Opioids in Hospitals." Respiratory depression is an identified patient safety issue. As The Joint Commission recently stated: "While opioid use is generally safe for most patients, opioid analgesics may be associated with adverse effects, the most serious effect being...

Astellas Submits Supplemental New Drug Application to FDA for Tarceva® as a First-Line Therapy in Genetically Distinct Form of Non-Small Cell Lung Cancer

2012-11-20 08:27:28

NORTHBROOK, Ill., Nov. 20, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Tarceva(®) (erlotinib) tablets for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor...

American Academy of Pain Medicine Safe Opioid Prescribing Course Proves Highly Effective

2012-11-14 16:26:10

93 Percent of Respondents Improve Prescribing Practices GLENVIEW, Ill., Nov. 14, 2012 /PRNewswire-USNewswire/ -- The American Academy of Pain Medicine (AAPM) released survey results today demonstrating the value of its Safe Opioid Prescribing Course as 93 percent of respondents report changing their practices after taking the course. Specifically, more than half of respondents to the survey reported that they have improved their practices, related to prescribing extended-release...